Research map: Concurrent icotinib and definitive radiotherapy followed by detection of an EGFR exon 20 insertion at disease progression in unresectable stage III EGFR S768I-mutant lung adenocarcinoma: a case report

Papers in this map

1. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer · Scott Joseph Antonia · 2017 · 4654 citations · Cited by this paper
2. Contrast-enhanced ultrasound-guided biopsy and perfusion monitoring for bladder involvement in relapsed multiple myeloma: a case report · 2026 · Related
3. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors · Lecia Van Dam Sequist · 2011 · 3602 citations · Cited by this paper
4. Ferroptosis in multiple myeloma: molecular mechanisms and therapeutic opportunities · 2026 · Related
5. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs · Mark G. Kris · 2014 · 1765 citations · Cited by this paper
6. Adaptive dosing of immunotherapy plus anti-angiogenic therapy in a nonagenarian with hepatocellular carcinoma: a case report with 10-year survival · 2026 · Related
7. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 · James Chih‐Hsin Yang · 2015 · 1004 citations · Cited by this paper
8. Predictors and prevalence of lateral supraclavicular lymph node metastases on [18F]FDG PET/CT in patients with locally advanced, or multifocal invasive ductal carcinoma of breast: potential impact on adjuvant radiotherapy targets · 2026 · Related
9. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology · Neal Ian Lindeman · 2018 · 954 citations · Cited by this paper
10. Case Report: a hypermetabolic mediastinal mass (SUVmax 16.7) mimicking malignancy with spontaneous resolution: an inflammatory myofibroblastic proliferation and diagnostic pitfall · 2026 · Related
11. Non–Small Cell Lung Cancer, Version 4.2024 · Gregory J. Riely · 2024 · 841 citations · Cited by this paper
12. Variations in histopathological and molecular subtypes between primary breast carcinoma and associated liver metastatic lesions · 2026 · Related
13. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis · Yuelun Zhang · 2016 · 816 citations · Cited by this paper
14. Perioperative outcomes and prognostic determinants in adult spindle cell/sclerosing rhabdomyosarcoma: implications of treatment intensity, surgical margins, and molecular heterogeneity · 2026 · Related
15. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer · Christian Diego Rolfo · 2021 · 684 citations · Cited by this paper
16. The combined compartmental maxillary resection: technique codification and preliminary multicenter series analysis · 2026 · Related
17. Structure-based classification predicts drug response in EGFR-mutant NSCLC · Jacqulyne Ponville Robichaux · 2021 · 492 citations · Cited by this paper
18. Baseline 18F-FDG PET/CT metabolic parameters and systemic inflammatory markers in advanced NSCLC treated with first-line immunotherapy: an exploratory retrospective analysis · 2026 · Related
19. Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC · Shun Lu · 2024 · 344 citations · Cited by this paper
20. Enhancing multimodal survival prediction: tri-modal learning with clinical knowledge integration via state space models · 2026 · Related
21. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer · Antonio Passaro · 2022 · 204 citations · Cited by this paper
22. Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant · HARMONi-A Study Investigators · 2024 · 198 citations · Cited by this paper
23. S768I Mutation in EGFR in Patients with Lung Cancer · Konstantinos Leventakos · 2016 · 74 citations · Cited by this paper
24. An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib · Wenxiao Jia · 2020 · 65 citations · Cited by this paper
25. Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma · Yoon Soo Chang · 2016 · 58 citations · Cited by this paper
26. Thoracic Radiotherapy Improves the Survival in Patients With EGFR -Mutated Oligo-Organ Metastatic Non–Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial · Hongfu Sun · 2024 · 55 citations · Cited by this paper
27. Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies · Alessandro Leonetti · 2023 · 54 citations · Cited by this paper
28. Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer · Donghyun Seo · 2024 · 25 citations · Cited by this paper
29. Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study · Leou Ismael Banla · 2023 · 13 citations · Cited by this paper
30. All EGFR mutations are (not) created equal: focus on uncommon EGFR mutations · Ullas Batra · 2022 · 7 citations · Cited by this paper
31. Utility of Next-Generation Sequencing in the Reconstruction of Clonal Architecture in a Patient with an EGFR Mutated Advanced Non-Small Cell Lung Cancer: A Case Report · Javier Simarro · 2022 · 4 citations · Cited by this paper
32. 1260P Efficacy and safety of sunvozertinib in prior platinum treated NSCLC patients with EGFR exon 20 insertion mutations: Primary analysis from the multinational WU-KONG1B pivotal study · Ludovic S. Doucet · 2024 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)